These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 12829890

  • 21. Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporin microemulsion.
    Filler G, Webb NJ, Milford DV, Watson AR, Gellermann J, Tyden G, Grenda R, Vondrak K, Hughes D, Offner G, Griebel M, Brekke IB, McGraw M, Balzar E, Friman S, Trompeter R.
    Pediatr Transplant; 2005 Aug; 9(4):498-503. PubMed ID: 16048603
    [Abstract] [Full Text] [Related]

  • 22. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
    Baboolal K.
    Transplantation; 2003 Apr 27; 75(8):1404-8. PubMed ID: 12717239
    [Abstract] [Full Text] [Related]

  • 23. Economic evaluation of sirolimus-based immunosuppressive regimens in kidney graft recipients.
    Niemczyk M, Nowak M, Pilecki T, Wyzgał J, Ziółkowski J, Zygier D, Paczek L.
    Transplant Proc; 2006 Apr 27; 38(1):74-7. PubMed ID: 16504668
    [Abstract] [Full Text] [Related]

  • 24. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels.
    Crespo M, Mir M, Marin M, Hurtado S, Estadella C, Gurí X, Rap O, Moral R, Puig JM, Lloveras J.
    Transplant Proc; 2009 Apr 27; 41(6):2115-7. PubMed ID: 19715848
    [Abstract] [Full Text] [Related]

  • 25. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG, Winoto J, Chhabra D, Parker MA, Leventhal JR, Kaufman DB.
    Transplantation; 2007 May 27; 83(10):1324-9. PubMed ID: 17519781
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK, Montagnino G, Del Castillo D, Margreiter R, Sperschneider H, Olbricht CJ, Krüger B, Ortuño J, Köhler H, Kunzendorf U, Stummvoll HK, Tabernero JM, Mühlbacher F, Rivero M, Arias M, European Tacrolimus vs Cyclosporin Microemulsion Renal Transplantation Study Group.
    Nephrol Dial Transplant; 2005 May 27; 20(5):968-73. PubMed ID: 15741208
    [Abstract] [Full Text] [Related]

  • 27. Addition of sirolimus to cyclosporine in long-term kidney transplant recipients to withdraw steroid.
    Citterio F, Sparacino V, Altieri P, Rigotti P, Calabrese S, Poli M, Vinti V, Segoloni GP.
    Transplant Proc; 2005 Mar 27; 37(2):827-9. PubMed ID: 15848545
    [Abstract] [Full Text] [Related]

  • 28. A 39-month follow-up study to evaluate the safety and efficacy in kidney transplant recipients treated with modified-release tacrolimus (FK506E)-based immunosuppression regimen.
    Han DJ, Park JB, Kim YS, Kim SJ, Ha J, Kim HC, Kim SJ, Moon IS, Yang CW.
    Transplant Proc; 2012 Jan 27; 44(1):115-7. PubMed ID: 22310592
    [Abstract] [Full Text] [Related]

  • 29. Ten years of treatment with tacrolimus is related to an excellent renal function, allowing monotherapy in a large proportion of cases: unicentric results of the tacrolimus versus cyclosporine A European Multicentric Study in kidney transplant patients.
    Morales JM, Andrés A, Dominguez-Gil B, Arriola M, Gutiérrez MJ, Hernández E, Ortuño T, Praga M.
    Transplant Proc; 2005 Nov 27; 37(9):3738-42. PubMed ID: 16386523
    [Abstract] [Full Text] [Related]

  • 30. Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era.
    Gralla J, Wiseman AC.
    Transplantation; 2009 Jun 15; 87(11):1712-9. PubMed ID: 19502965
    [Abstract] [Full Text] [Related]

  • 31. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ, Felipe CR, Tedesco-Silva H, Osmar Medina-Pestana J.
    Pharmacotherapy; 2016 Feb 15; 36(2):152-65. PubMed ID: 26799522
    [Abstract] [Full Text] [Related]

  • 32. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats.
    Lloberas N, Torras J, Alperovich G, Cruzado JM, Giménez-Bonafé P, Herrero-Fresneda I, Franquesa Ml, Rama I, Grinyó JM.
    Nephrol Dial Transplant; 2008 Oct 15; 23(10):3111-9. PubMed ID: 18469305
    [Abstract] [Full Text] [Related]

  • 33. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.
    Exp Clin Transplant; 2008 Jun 15; 6(2):113-7. PubMed ID: 18816237
    [Abstract] [Full Text] [Related]

  • 34. Statins benefit outcomes of renal transplant recipients on a sirolimus-cyclosporine regimen.
    Lisik W, Schoenberg L, Lasky RE, Kahan BD.
    Transplant Proc; 2007 Dec 15; 39(10):3086-92. PubMed ID: 18089328
    [Abstract] [Full Text] [Related]

  • 35. Low-dose tacrolimus/sirolimus and steroid withdrawal in heart recipients is highly efficacious.
    Meiser B, Kaczmarek I, Mueller M, Groetzner J, Weis M, Knez A, Stempfle HU, Klauss V, Schmoeckel M, Reichart B, Ueberfuhr P.
    J Heart Lung Transplant; 2007 Jun 15; 26(6):598-603. PubMed ID: 17543783
    [Abstract] [Full Text] [Related]

  • 36. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients.
    Włodarczyk Z, Wałaszewski J, Perner F, Vitko S, Ostrowski M, Bachleda P, Kokot F, Klinger M, Szenohradsky P, Studenik P, Navratil P, Asztalos L, Rutkowski B, Nagy KK, Hickey D.
    Ann Transplant; 2002 Jun 15; 7(3):28-31. PubMed ID: 12465429
    [Abstract] [Full Text] [Related]

  • 37. The combination of sirolimus and cyclosporine does not delay initial renal graft function recovery.
    Hsu HJ, Tian YC, Chen YC, Lai BC, Fang JT, Yang CW, Wu MS.
    Ren Fail; 2008 Jun 15; 30(3):303-6. PubMed ID: 18350450
    [Abstract] [Full Text] [Related]

  • 38. Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy.
    Anil Kumar MS, Heifets M, Fyfe B, Saaed MI, Moritz MJ, Parikh MH, Kumar A.
    Transplantation; 2005 Sep 27; 80(6):807-14. PubMed ID: 16210969
    [Abstract] [Full Text] [Related]

  • 39. The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study.
    Ekberg H, Mamelok RD, Pearson TC, Vincenti F, Tedesco-Silva H, Daloze P.
    Transplantation; 2009 May 15; 87(9):1360-6. PubMed ID: 19424036
    [Abstract] [Full Text] [Related]

  • 40. Pharmacokinetic variability of sirolimus in Taiwanese renal transplant recipients.
    Chueh SC, Wang SM, Lai MK, Chen J.
    Transplant Proc; 2004 Sep 15; 36(7):2058-9. PubMed ID: 15518745
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.